Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Expands By 37.9%

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 5,752,164 shares, an increase of 37.9% from the December 15th total of 4,170,658 shares. Currently, 10.6% of the shares of the company are sold short. Based on an average daily trading volume, of 857,161 shares, the short-interest ratio is currently 6.7 days. Based on an average daily trading volume, of 857,161 shares, the short-interest ratio is currently 6.7 days. Currently, 10.6% of the shares of the company are sold short.

Astria Therapeutics Trading Down 2.7%

Shares of ATXS stock opened at $12.47 on Friday. Astria Therapeutics has a twelve month low of $3.56 and a twelve month high of $13.29. The stock has a market cap of $711.85 million, a P/E ratio of -5.83 and a beta of 0.01. The stock has a 50 day moving average of $12.77 and a 200 day moving average of $9.67.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.14). The business had revenue of $0.71 million during the quarter, compared to analyst estimates of $10.67 million. On average, research analysts predict that Astria Therapeutics will post -1.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ATXS shares. Lifesci Capital lowered shares of Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Astria Therapeutics in a research note on Wednesday, October 8th. Oppenheimer lowered Astria Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Jefferies Financial Group downgraded Astria Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $30.00 to $13.00 in a report on Tuesday, October 14th. Finally, Cantor Fitzgerald lowered Astria Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Wednesday, November 12th. Two equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $24.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in shares of Astria Therapeutics by 4,607.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company’s stock worth $9,091,000 after acquiring an additional 1,660,039 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Astria Therapeutics by 9.6% in the 3rd quarter. Vestal Point Capital LP now owns 4,956,000 shares of the biotechnology company’s stock valued at $36,080,000 after purchasing an additional 434,000 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in Astria Therapeutics by 59.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,069,530 shares of the biotechnology company’s stock worth $5,733,000 after purchasing an additional 400,000 shares during the period. Affinity Asset Advisors LLC purchased a new position in Astria Therapeutics during the second quarter worth approximately $1,608,000. Finally, Adage Capital Partners GP L.L.C. boosted its position in Astria Therapeutics by 48.8% during the second quarter. Adage Capital Partners GP L.L.C. now owns 875,000 shares of the biotechnology company’s stock worth $4,690,000 after purchasing an additional 286,800 shares in the last quarter. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.